In a patient who recently received an ocrelizumab (Ocrevus) infusion and now presents with sore throat, fatigue, and generalized weakness, what evaluation and management steps are recommended?

Evaluation and Management of Post-Ocrelizumab Infusion Symptoms

This patient requires immediate evaluation for infection, as sore throat, fatigue, and weakness following ocrelizumab infusion most likely represent an upper respiratory tract infection in an immunosuppressed individual, though delayed infusion reactions and serum sickness must also be considered.

Immediate Assessment

Timing is Critical

Determine exactly when symptoms began relative to the infusion:

• Within 24 hours: Likely a delayed infusion reaction 1
• 5-14 days post-infusion: Consider serum sickness/serum sickness-like reaction 2
• Any time during treatment: Infection is the primary concern 1

Key Clinical Features to Assess

For Infection (Most Common):

• Fever, productive cough, dyspnea (respiratory tract infection)
• Pharyngeal exudate, lymphadenopathy (bacterial pharyngitis)
• Vesicular lesions (herpes simplex/zoster) 1
• Severity of immunosuppression based on time since last infusion

For Delayed Infusion Reaction:

• Myalgia, arthralgia, headache, rash occurring 1-14 days post-infusion 3
• Usually self-limited, resolving within days

For Serum Sickness:

• Generalized arthralgias with weakness
• Rash, fever
• Elevated inflammatory markers (ESR, CRP)
• Occurs typically after 2nd or 3rd infusion 2

Diagnostic Workup

Essential Laboratory Tests

• Complete blood count with differential: Check for neutropenia (can occur with ocrelizumab) 4, 5
• Inflammatory markers: ESR, CRP (elevated in serum sickness and infection)
• Throat culture or rapid strep test: If pharyngitis suspected
• Viral PCR panel: If herpes infection suspected 1

Additional Testing Based on Severity

• Chest X-ray: If respiratory symptoms present (ocrelizumab increases risk of lower respiratory tract infections) 1
• Immunoglobulin levels: If recurrent infections or prolonged symptoms 1

Management Algorithm

If Infection is Confirmed or Highly Suspected

Delay next ocrelizumab dose until infection fully resolves 1. This is non-negotiable.

Upper Respiratory Tract Infection (most common scenario):

• Supportive care for viral URI
• Antibiotics only if bacterial pharyngitis confirmed
• Close monitoring for progression to lower respiratory tract

Herpes-Related Infection:

• Initiate antiviral therapy immediately (acyclovir or valacyclovir)
• Discontinue or withhold ocrelizumab if serious herpes infection 1
• Serious herpes infections (CNS involvement, disseminated disease) require hospitalization

Severe or Worsening Infection:

• Hospitalize for IV antibiotics
• Broad-spectrum coverage initially
• Monitor for sepsis

If Delayed Infusion Reaction

Symptoms typically include myalgia, arthralgia, headache, fever, rash, and fatigue beginning 1-14 days after infusion 3:

• Symptomatic management with NSAIDs or acetaminophen
• Self-limited, usually resolves within 24-48 hours
• Does not require ocrelizumab discontinuation
• Consider premedication adjustment for next infusion

If Serum Sickness Suspected

Clinical presentation: generalized weakness, arthralgias, elevated inflammatory markers, negative infectious workup 2:

• Initiate corticosteroid taper (prednisone 40-60 mg daily, taper over 2-3 weeks)
• Add NSAIDs for additional symptom control
• Expect dramatic improvement within days 2
• Consider switching to alternative MS therapy if recurs

Critical Red Flags Requiring Immediate Action

• Fever with neutropenia (ANC <1.0): Medical emergency requiring immediate hospitalization, broad-spectrum antibiotics, and G-CSF 5
• Respiratory distress: Evaluate for pneumonia or severe bronchospasm
• Neurological symptoms: Consider CNS herpes infection (encephalitis/meningitis) - requires immediate hospitalization and IV acyclovir 1
• Persistent high fever with hepatosplenomegaly: Consider hemophagocytic lymphohistiocytosis (rare but life-threatening) 6

Prevention for Future Infusions

Optimize premedication protocol to reduce infusion reactions 7:

• Night before: cetirizine 10 mg, ranitidine 75 mg, increased hydration
• Morning of infusion: repeat oral medications
• Pre-infusion: IV methylprednisolone 100-125 mg, IV diphenhydramine 50 mg, acetaminophen 650 mg 1, 7

Infection screening before each infusion 8:

• Active infection is an absolute contraindication to proceeding with infusion 1
• Monitor immunoglobulin levels if recurrent infections

Common Pitfall

Do not assume all post-infusion symptoms are benign infusion reactions. Ocrelizumab significantly increases infection risk (58-70% of patients experience infections) 1, with upper respiratory infections being most common (40-49% of patients). The immunosuppressive effects persist between doses, making patients vulnerable throughout the treatment course.